Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
194 Cards in this Set
- Front
- Back
What organs does the Thyroid axis consist of?
|
Hypothalamus
Anterior Pituitary Thyroid gland |
|
Thyroid Releasing Hormone target
|
anterior pituitary
|
|
Thyroxine
|
storage form of T3 and T4
|
|
T4 conversion to T3
|
In liver and target cells, it is deiodinated
|
|
TRH is synthesized from where?
|
paraventricular nuclei of the hypothalamus
|
|
What does the TRH do?
|
induces quick release of TSH from anterior pituitary thyrotrophs
|
|
Hypothalamic hypothyroidism
|
lack of TRH
|
|
What thyroidtrophs affect the anterior pituitary?
|
TRH: MOST EFFECTIVE
somatostatin (inhibitory growth hormone) Dopamine: inhibitory Cortisol: inhibitory estrogen: stimulatory |
|
TSH secretion
|
episodic and pulsatile, onset of sleep induces secretion
|
|
TSH structure
|
A glycoprotien: alpha and beta chain
beta chains are what convey specificity of activity of hormone (alphas are somewhat the same) |
|
Target of TSH
|
Thyroid glad cells
|
|
Actions of TSH
|
increases vascular flow
increased the active transport uptake of iodide increases thyroid cell production of hormones release t3 and t4 |
|
Thiocyanates
|
pharmaceutical that slows the iodide pump...incapacitating the formation of T3 and T4
|
|
Perchlorates
|
drug that competitively inhibits iodide up
|
|
thyroid peroxidase
|
oxidizes iodide and slows the system
|
|
What does oxidation of iodide permit?
|
iodination of tyrosine residues of thyroglobulin, a key step in some diseases.
|
|
Thiouricil
|
prevents binding of iodine to tyrosine residues of thyroglobulin
|
|
what is important in the activities of tri-iodothyronine (T3) and tetraiodothyronine (T4)
|
The placement of the I groups
rT3= reversed, I in wrong place, biologically inactive T3 |
|
Where does thyroglobulin move to?
|
follicular lumen
|
|
what is the majority of the hormone that is secreted by the thyroid?
|
T4 (T3 is secreted in very small amounts)
|
|
What protien is T3 bound to?
|
T3TBG (thyroid binding globulin)
|
|
What proteins do T4 bind to?
|
60% T4TBG
30% T4TBPA (precursor to TBG) 10% lossely to albumin |
|
What can cause a thyroid imbalance due to T4's protien binding
|
albuminuria
|
|
where is there the formation of monoiodo and diiodothyronines?
|
follicular lumen
|
|
What are the effects of T3 and T4 release?
|
Calorigenesis
alertness, anxiousness increases catecholamine receptors on heart- increases HR and force of contractibility increases vigor of respiration increases hematopoeisis |
|
What is the connection between T3 and vitamine A
|
T3 is necessary to convert carotine to vitamine A to retinene
|
|
Why is there yellow skin in hypothyroidism
|
because serum carotene increases since it's not converted to Vitamin A
The Sclera stays white! |
|
What hormones does T3 and T4 potentate (support) ?
|
insulin- increase in anabolic activity
catecholamines: increase in glycogenolysis with resultant hyperglycemia |
|
What happens when there is no T3 to the retina?
|
There is no retinal pigment due to no retinene
|
|
Thyrotoxicosis
|
structural and functional alterations in tissues due to extensive hyerthyroidism
|
|
Graves Disease
|
most common type of hyperthyroidism
thyroid gland is uniformly enlarged exophthalmus ocurs in about 50% of patients |
|
Thyroid storm
|
accelerated hyperthyroidism due to surgery, myocardial infarction, or drugs
|
|
Difference between thyroid storm and pheochromocytoma?
|
symptoms of thyroid storm lasts for days
|
|
Signs and Symptoms of Hypothyroidism
|
slow growth, mental retardation in children
slowing down of metabolic activities, coarse features due to deposition of GAGs, edema in face and tongue. |
|
Treatment of Hypothyroidism
|
Synthroid
|
|
Activities of ionized calcium
|
proper coagulation
stabilization of membranes intercellular adhesion muscle contraction neurotransmitter transmitter maintenance of teeth and bones |
|
Two pools in skeletal storage?
|
Stable pool
Labile pool |
|
Stable pool
|
where most of the calcium in the skeletal storage is found
Mature bone storage |
|
Labile Pool
|
young, newly formed bone, about 1% of skeletal storage
constantly being remodled readily exchangeable to supplement ECT Ca++ |
|
Calcium concentration in ECF norms
|
8.5-10.5 mg/dL
|
|
Three dietary Ca++ intake forms- circulating ECF Ca++ (about 1% of total Ca)
|
1. Ionized fraction (46%)
2. Protein bound fraction (46%) 3. Complexed Fraction (8%) |
|
Ionized fraction of Ca++
|
only biologically active form of Ca
46% of the 1% (ECF) of Ca++ in body |
|
Protein Bound Fraction of Ca++
|
biologically inert but readily available
bound to albumin and to some extent globulin 46% of the 1% |
|
If albumin is low, how does this affect Ca?
|
The protein bound fraction of Ca++ will be decreased thus if there is hypokalcemia, must look at albumin levels.
|
|
Complexed fraction of Ca++
|
finite reserve
complexed to organic and inorganic acids about 8% of ECF Ca insignificant except for in disease |
|
Diffusible Fraction
|
sum of ionized and complexed fractions of Ca++
This Ca can get into the cell |
|
Non Diffusible Fraction
|
the protein bound fraction that cannot get into the cell and stays in bloodstream.
|
|
Three Calcitropic Hormones
|
1. Vitamin D3
2. Parathyroid Hormone (PTH) 3. Calcitonin |
|
Vitamin D2
|
ingested in milk
not biological active form precursor in skin to Vitamin D3 |
|
Vitamin D3
|
Activated by sun from D2.
|
|
First step in Activation of Vitamin D
|
Liver: hydroxylation of D3 to 25-OH vit D (CALCIDIOL)
|
|
Second step in activation of Vitamin D
|
Kidney: hydroxylation of calcidiol to 1,25-dihydroxy vit D or CALCITROL
|
|
What stimulates the hydroxylation of calcidiol in the kidney?
|
Parathyroid Hormone (PTH)
Insulin Growth Factor 1 |
|
What inhibits the hydroxylation of calcidiol in the kidney?
|
fibroblast derived growth factor 23
high blood levels of calcium and phosphate |
|
What are the target cells that absorb Ca?
|
small intestines
|
|
Actions of active Vitamin D3
|
increases uptake of calcium in gut
alters bone reabsorption rate |
|
Source of PTH?
|
Chief cells of the parathyroid gland
|
|
Stimulus for the release of PTH?
|
decreased plasma calcium levels
|
|
What are the two receptors for PTH?
|
1. PTH1
2. PTH2 |
|
What does PTH1 receptor recognize?
|
PTH and PTHrP (PTH related protien)
|
|
Which receptor ONLY recognizes PTH?
|
PTH2 receptor
|
|
PTHrP
|
PTH related protein
needed for mineralization of chondrocytes and development of mammary glands, skin and hair follicles |
|
What is produced in abundance in malignant tumors? (particularly alarming in mammograms)
|
PRHrP: if there are Ca deposits seen in mammograms, signifies malignancy
|
|
Actions of PTH
|
Increase ECF Ca++ by:
1. Increases bone reabsorption 2. increases reabsorption of Ca out of the kidney (instead of eliminating it in urine) 3. facilitates kidney hydroxylation of Vitamin D |
|
Calcitonin
|
Opposes PTH:
1.Decreases osteoclastic activity 2. increases the laying down of bony matrix |
|
Osteoclasts
|
a type of bone cell that removes bone tissue by removing its mineralized matrix and breaking up the organic bone
|
|
Hyperparathyroidism: major two characterizations
|
hypercalcemia and hypophosphatemia
|
|
Etiologies of Primary Hyperthyroidism
|
1. unresolved
2. genetic link: MEN1 and MEN2 3. Adenomas 4.hyperplasia 5. Carcinomas |
|
Does the severity of hypercalcemia parallel the degree of parathyroid tissue involvement?
|
yes
|
|
Kidney manifestation from Hyperparathyroidism
|
1. Nephrolithiasis: tendancy towards kidney stones
2. Pyelonephritis: inflammation of renal tubules. Leads to water loss and dehydration (polydipsia and polyuria) |
|
Skeletal manifestations of Hyperparathyroidism
|
gross demineralizatin
atraumatic fractures deep bone pain joint pain |
|
Neuropyschiatric manifestations of hyperparathyroidism
|
mental fatigability
emotional lability irritability |
|
GI manifestations of hyperparathyroidism
|
anorexia
nausea vomiting weight loss |
|
Cardiovascular manifestations of Hyperparathyroidism
|
severe hypertension: laying down of Ca++ in blood vessels
|
|
Ocular Manifestations of Hyperparathyroidism
|
Distiguishes disease from others:
1. Band/Limbus keratopathy: Ca deposits around cornea |
|
What must you rule out to get Hyperparathyroidism?
|
Vit D intoxication
Sarcoidosis Multiple Myeloma Metastatic or Primary Carcinomas Thyrotoxicosis All of these present increased serum Ca |
|
Differential Diagnosis of Hyperparathyroidism:
POLYDIPSIA and POLYURIA |
Diabetes
|
|
Differential Diagnosis of Hyperparathyroidism:
Demineralization, emotional lability, elevated blood pressure |
Cushings Disease (hyper-corticolism)
|
|
Differential Diagnosis of Hyperparathyroidism:
Anorexia, nausea, vomiting, weight loss |
Addisons (hypocorticolism, decrease in cortisol)
|
|
Differential Diagnosis of Hyperparathyroidism:
long standing hypercalcemia |
Graves disease due to long term thyrotoxicosis
|
|
Calcium levels in serum in Hypoparathyroidism
|
less than 7mg/dL
|
|
What does Hypoparathyroidism sometimes coexist with?
|
Addison's disease
|
|
Systemic signs of Hypoparathyroidism
|
Tetany
Trousseaus sign Chovstek's sign Hyperreflexia prolonged QT interval |
|
Ocular manifestation of Hypoparathyroidism
|
PSC
|
|
Vitamin D deficiency
|
Rickets in children, osteomalacia in adults.
Decreased absorption of Calcium due to decreased Vitamin D |
|
Osteoporosis- signs
|
rounding of the back and difficulty moving
|
|
Causes of osteoporosis
|
Decreased estrogen in females, not enough calcium ingested early in life
usually runs in families |
|
Somatomedins
|
Growth factors
promote or facilitate growth and repair IGF-1 and IGF-2 |
|
Growth Hormones
|
hormone that promotes linear growth
|
|
IGF-1
|
Somatomedin
mediates effects of growth hormones |
|
What is IGF-1 structurally similar to?
|
Proinsulin/insulin (tertiary structure)
receptor characteristics similar to insulin receptor considerable overlap in cellular reactions to both ligands |
|
How does IGF-1 circulate in plasma?
|
As a complex with IGFBP-3 (binding protien) that extend the 1/2 life of IGF-1 and modulates action
|
|
What is the first step in diagnosing a growth failure, test-wise?
|
Measuring IGPFB-3 and IGF-1 since GH testing is expensive.
|
|
What is a critical determinant of growth?
|
locally produced IGF-1
|
|
How are IGF-1 Receptor and the insulin receptor correlated?
|
both are stimulated by the same stimulus for up and down regulation. (If there is a deficiency in one, there will be a deficiency in the other).
|
|
What receptor is IGF-II similar to?
|
mannose 6 phosphate receptor
|
|
Which receptors can IGF-II bind to?
|
IGF-II receptor, IGF-1 receptor, insulin receptor
|
|
Where is IGF-1 and IGF-II synthesized primarily?
|
Liver, but also in other tissues where it has paracrine function
|
|
What controls IGF-1 synthesis?
|
Growth Hormone
Insulin Progesterone |
|
is IGF-II synthesis dependent on growth hormone?
|
no, regulation unknown
|
|
Effects of IGF-I:
Muscle and metabolism |
stimulates RNA/DNA synthesis for production of cartilage and preteoglycans
in muscle, equivalent to insulin to promote protien synthesis |
|
Effects of IGF-I:
adipose tissue |
acts like insulin to increase triglyceride and glucose uptake
|
|
Effects of IGF-I:
cells |
inhibits cell death
induces differentiation facilitate immune cell regulation mitogenic responses |
|
Effects of IGF-I:
Systemic/Organismal effects |
Human longevity
wide distribution of IGF-I receptors throughout body |
|
Effects of IGF-I:
Brain aging |
sustains neuron health
contributes to B-amyloid clearance |
|
Effects of IGF-II
|
Key regulatory of pluripotent human embryonic stem cells
important in early gestation |
|
What is secreted by the hypothalamus in the somatotropin axis?
|
GHRH: Somatoliberin
GHIF: Somatostatin |
|
Somatoliberin, where is it secreted from?
|
GHRH
Growth Hormon Releasing hormone secreted from the arcuate nucleus of hypothalamus |
|
What is the half life of somatoliberin?
|
50 minutes
|
|
Somatostatin, where is it secreted from?
|
GHIF
Growth Homrone Inhibitory Factor secreted from the paraventricular area of hypothalamus also from various areas of the brain and pancreas and areas of GI tract |
|
Target of somatotrophs?
|
Anterior Pituitary
|
|
What does the anterior pituitary secrete in the somatotrophin axis?
|
Growth Hormone
|
|
What is the secretion of GH like?
|
Pulsatile and episodic
Peak is 1-4 hours after onset of sleep circulates 20-50 minutes |
|
What are the insulin-like features of GH?
|
Increases chondrogenesis
increases skeletal growth increases cell proliferation |
|
What are anti-insulin features of GH?
|
Increases lipolysis in adipose tissue
increase beta oxidation which is ketogenic |
|
Influence of GH on carbohydrates
|
increases gylcogenolysis
increases plasma glucose increases receptor resistance to glucose entry (hyperglycemia) |
|
Why is it most difficult to manage diabetics at adolescence?
|
They have twice as much growth hormone which increases the chances of ketoacidosis
both insulin deprived and has an increase in growth factor |
|
What hormone causes the close of epipheseal plates?
|
Estrogen
|
|
Facilitory homrones for Linear Growth
|
GH
IGF-1 Insulin T3 and T4 Androgens |
|
Inhibitory hormones for Linear Growth
|
Estrogens
Glucocorticoids |
|
Alcohol's effect on IGF-1
|
long term use: inhibits production in liver
short term use: alters the function in brain, suppressing release of hormones involved in onset of puberty |
|
Dwarfism
|
height that is less than 2 standard deviations from the mean
|
|
Gigantism
|
height greater than 2 SD from the mean that occurs before the closing of epiphyses of long bones
|
|
Acromegaly
|
growth that occurs after the closure of epiphyses so girth increases
Elevated IGF-I levels and excess GH levels occurs secondary to PITUITARY ADENOMA or HYPERPLASIA |
|
signs of Acromegaly
|
enlarged hands, feet, coarsening of facial features, sweating, oily skin, fatigue, weight gain
Diabetics 25% of the time Hyperinsulemia Goiters HTN, cariomegaly |
|
With any visual field defect, what must you rule out?
|
Pituitary adenoma!!!! *****
|
|
What is the most common type of pituitary adenoma?
|
Prolactinoma (60%)
milky secretion from the nipples of both males and females |
|
Differential diagnosis for pituitary adenoma?
|
Cushings Disease- there may be an excess of corticotrophs and ACTH
|
|
Ocular signs and symptoms of Pituitary adenoma
|
Headache
Bilateral Hemianopsia Papilledema chromatopsias (some loss of color vision) |
|
Cushings Syndrome
|
excess Cortisol due to Pituitary tumor, adrenal tumor, or non-axial carcinoma
|
|
Clinical manifestations of Cushings Syndrome
|
hyperglycemia (cortisol excess)
moon face, buffalo hump thin limbs HTN with L ventrical hypertrophy hyperpigmentation |
|
Increase Cortisol WITH increase ACTH
|
Cushings Syndrome due to Pituitary tumor
|
|
Increased Cortisol WITH OUT increase of ACTH
|
Cushings due to adrenal tumor
|
|
20-hydroxylase deficiency
|
all corticosteroid production is affected due to deficiency in mobilization of cholesterol
|
|
3-beta-hydroxysteroid deficiency
|
decreases in cortisol, aldosterone, androgens due to no conversion of pregnenolone to progesterone
|
|
17-alpha-hydroxylase deficiency
|
increase of corticosterone (HTN), decrease in aldosterone and cortisol and androgens. Children remain infantile
|
|
21-hydroxylase deficiency
|
MOST COMMON CAUSE
decrease cortisol and aldosterone, increase of 18-OH corticosterone and androgens |
|
11-beta-hydroxylase deficiency
|
decrease in cortisol, increase in HTN, Virilization, 11-deoxycorticosterone
|
|
Addisons Disease
|
Hypocorticolism due to adrenal failure
Decrease in cortisol, aldosterone |
|
Presentation of Addison's Disease
|
urninary loss of Na: hypovolemia, hypotension
vomiting and diarrhea increase BUN Abdominal pain weakness and weight loss skin pigmentation: VITILIGO hypoglycemia |
|
Hyperpigmentation due to Primary Addison's disease
|
melanocyte-stimulating hormone (MSH) and adrenocorticotropic hormone (ACTH) share the same precursor molecule, Pro-opiomelanocortin (POMC). After production in anterior pituitary gland, POMC gets cleaved into Gamma-MSH, ACTH and Beta-lipotropin. The subunit ACTH undergoes further cleavage to produce Alpha-MSH, the most important MSH for skin pigmentation. In secondary and tertiary forms of Addison's, skin darkening does not occur.
|
|
Primary Aldosteronism
|
excessive production of aldosterone due to adrenal hyperplasia, adenoma or carcinoma
|
|
Major signs of Aldosteronism
|
Hypertension
Hypokalemia Metabolic Alkalosis |
|
other signs of Aldosteronism
|
Chovsteks sign
Trousseaus sign frontal headache muscle weakness nocturia polydipsia and polyuria |
|
Pathogenesis for Metabolic Alkalosis in primary aldosteronism
|
1. excessive K secretion in exchange for Na+ reabsorption, K seen in urine
2. H moves intracellularly to comensate loss of K |
|
Secondary aldosteronism
|
due to reduced renal flow, excessive renin production, or estrogen therapy
|
|
Signs of Secondary Aldosteronism
|
essential and malignant HTN, retinopathy
|
|
Pheochromocytoma
|
Adenomic tumor in which the size DOES NOT correlate with the severity.
|
|
Characterizations of Pheochromocytoma
|
HTN in paroxysms, postural fall
flushing of face pounding headaches lasts about 15 minutes intermittent hyperglycemia (200-325) |
|
Normal Fasting Blood Glucose
|
less than 100 mg/dL
|
|
Impaired glucose tolerance
|
100-126 mg/dL
|
|
Hyperglycemia
|
>126 mg/dL
need further testing |
|
Normal Hemoglobin A1C results
|
3.5-5.6%
|
|
Characteristics of Type I Diabetes Melitus
|
severe hyperglycemia
tendancy towards ketoacidosis renal involvement neovascularization of retina |
|
Genetics of Diabetes Melitus
|
HLA antigens: HLA-DQw2/8
highest incidence in Scandonavia and sardinia |
|
Markers for distruction of Pancreas in DM
|
T cells mediate the destruction of beta cells in pancreas, antibodies are markers
|
|
hyperglycemia
moon face buffalo hump HTN Skin hyperpigmentation |
Cushings Syndrome (hypercortisolism)
|
|
thin with muscle weakness
hyponatremia (loss of salt) hypotension increased BUN vomitting and diarrhea dehydration hypoglycemia |
Addison's Disease (hypocortisolism)
|
|
severe frontal headache
muscle weakness nocturia and polydipsia and polyurea HTN hypokalemia metabolic acidosis Chovstek's sign Trousseau's sign |
Primary Aldosteronism (ecess aldosterone)
|
|
HTN
Retinopathy malignant HTN |
Secondary Aldosteronism (could be due to oral contraceptives)
|
|
Paroxysms of HTN
Overwhelming feeling of foom Palpitations flushing hyperglycemia (can be intermittent) all episodes last about 15 minutes |
Pheochromocytoma
|
|
o Background retinopathy – dot hemorrhage in middle layer of retina
o Proliferative retinopathy o Vitreous hemorrhage o Retinal detachments |
Type 1 DM
|
|
• cardiovascular disease
• hypertension • adult onset diabetes • obesity • stroke |
CHOAS
|
|
• Hyperglycemia
• Hyperinsulinemia • Dyslipidemia • hypertension |
Syndrome X
|
|
o goiter
o eye problems – dryness, difficulty in blinking o exophthalmus – eye protrudes out of orbit o dermatological problems – dry, scaly, red skin in lower leg area – called myxedema – a characteristic sign o tend to tremor and feel tired |
Grave's Disease- diffuse toxic goiter due to hyperthyroidism
|
|
Levothyroxine
|
Pure synthetic T4 that is converted to T3 in the body
Drug of choice for long term Oral |
|
Liothyronine
|
Pure synthetic T3
Short half life so drug of choice for HYPOTHYROID CRISIS |
|
Thyroglobulin
|
Peripheral extract of pig thyroid...allergy issues
|
|
Thyroid
|
natural preparation of pig or cow thyroid glands for T3 and T4
not drug of choice |
|
Loitrix
|
Combo of T3 and T4, not drug of choice
|
|
Propylthiouracil
|
inhibits conversion of T4 to T3, antioxidant drug that interferes with the organification of Iodine salts
|
|
Methimazole
|
antioxidant drug that interferes with the organification of iodine salts
antithyroid |
|
Adverse effects of anti-thyroid drugs
|
Agranulocytosis: failure of the bone marrow to make enough
white blood cells (neutrophils). |
|
Lugol's solution
|
Iodine solution given in large doses to treat hyperthyroidism
Inhibits release of thyroid hormone |
|
Paresthesias of the extremities
tetany laryngospasms increased neuromuscular excitibility convulsions hypocalcemia |
Hypoparathyroidism
|
|
Muscle weakness
life threatening cardiac arrhythmia soft tissue calcification constipation nausea hypercalciuria (renal) |
hyperparathyroidism
|
|
Calcintonin used for treatment
|
Hyperparathyroidism
idopathic hypercalcium vit D intoxity osteoclastic bone metastases |
|
Paget's disease
|
bones become vascularized and weakened- can use calcitonin as treatment
|
|
Fosamax
|
oral bisphosphonate used in prevention of osteoporosis
|
|
Aredia
|
IV administered bisphosphonate used for hypercalcemia of malignancy
|
|
Bisphosphonates
|
Drug that inhibit the digestion of bone by osteoclasts
|
|
Why do Androgenic Drugs need to be modified?
|
Testosterone given by injection is too quickly absorbed, metabolized and excreted and given orally is ineffective due to first pass metabolism in liver
|
|
What chemical modification is made to testosterone?
|
Esterification of 17-beta-hydroxyl group with carboxylic acids
Alkylation at 17-alpha position for oral administration |
|
What type androgenic drug is given intramuscilarly and what does the lipid solubility correlate with?
|
Testosterone Esters
the length of the carbon chain |
|
Methenolone Acetate
|
C-1 methyl group oral testosterone ester
|
|
Testosterone undecanoate
|
abosrbed via the lymphatic circulation
oral testosterone ester |
|
C17 Alkylated Testosterone Derivatives
|
All orally active
|
|
Testosterone Cypionate
Testosterone Enanthate Testosterone Propionate Methyltestosterone |
1:1 Androgenic:anabolic activity
|
|
Fluoxymestrone
Oxymetholone Ethylesternol Oxyandrolone* Nandrolone stanozolol |
more than 1:1 androgenic: anabolic activity
|
|
Dihydrotestosterone
|
what testosterone can be converted to in some tissues
binds to androgen receptor protein 10x more tightly than testosterone |
|
Endogenous Anti-androgens
|
Estrogen
progesterone norprogesterone |
|
GnRH Antagonists
|
Androgen synthesis inhibitors
inhibits LH release (luteinizing hormone that causes making of testosterone) |
|
GnRH agonist
|
androgen synthesis inhibitor
inhibits LH release due to receptor downregulation |
|
Spironolactone
Ketoconazole Liarozole |
Inhibits cytochrome P450 enzymes involved in steroid biosynthesis (Androgen synthesis inhibitor)
|